Investigational drug · Phase 2
LT3001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Ischemic Stroke.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
7
Any phase or sponsor naming "LT3001"
First trial start
2022
Aug 11, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LT3001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "LT3001" as an intervention, largest first.
- Efficacy and Safety of LT3001 on Treating the Acute Ischemic StrokePivotal-lookingRecruiting
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05686642 · 300 participants (planned) · Start Apr 6, 2023 · Primary completion Dec 10, 2026
Drug: LT3001 Drug:high dose; Placebo and 1 more · For: Acute Ischemic Stroke
Sites: Beijing, China; Guangzhou, China; Luoyang, China · 28 sites in all
- A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic StrokePivotal-lookingNot yet recruiting
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT07754825 · 300 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2027
Drug: LT3001 Drug:high dose; LT3001 Drug: low dose and 1 more · For: Acute Ischemic Stroke
Sites: Beijing, China
- A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS SubjectsCompleted
Lumosa Therapeutics Co., Ltd.Industry
NCT05403866 · 89 participants · Start Aug 17, 2022 · Primary completion May 23, 2025
Drug: LT3001 Drug Product; Placebo · For: Acute Ischemic Stroke
Sites: Chattanooga, Tennessee
- A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVTActive, not recruiting
Lumosa Therapeutics Co., Ltd.Industry
NCT05198323 · 66 participants (planned) · Start Aug 11, 2022 · Primary completion Dec 31, 2026
Drug: LT3001 Drug Product; Placebo · For: Acute Ischemic Stroke
Sites: Chattanooga, Tennessee; Taichung, Taiwan
Lumosa Therapeutics Co., Ltd.Industry
NCT04809818 · 65 participants · Start Mar 21, 2021 · Primary completion Aug 5, 2021
Drug: LT3001 drug product; Placebo and 4 more · For: Acute Ischemic Stroke
Sites: Cypress, California
- A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AISCompleted
Lumosa Therapeutics Co., Ltd.Industry
NCT04091945 · 24 participants · Start Jan 27, 2020 · Primary completion Feb 22, 2021
Drug: LT3001 Drug Product; Placebo · For: Acute Ischemic Stroke
Sites: Lexington, Kentucky; Edison, New Jersey; Columbus, Ohio · 10 sites in all
Lumosa Therapeutics Co., Ltd.Industry
NCT07890298 · 10 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2027
Drug: LT3001 Drug Product · For: Acute Ischemic Stroke
Sites: Taichung, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Intravenous Odatroltide for Acute Ischemic Stroke Within 24 Hours of Onset: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
Chao AC, Lee TH, Pettigrew LC, et al. · Drug Des Devel Ther 2024
- Effects of the New Thrombolytic Compound LT3001 on Acute Brain Tissue Damage After Focal Embolic Stroke in Rats.
Jiang Y, Ji Y, Zhou IY, et al. · Transl Stroke Res 2024
Also in development for Acute Ischemic Stroke
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
- JX10Phase 31 trial
Corxel Pharmaceuticals · Acute Ischemic Stroke
- SHPL-49Phase 31 trial
Shanghai Hutchison Pharmaceuticals Limited · Acute Ischemic Stroke
- LT3001 DrugPhase 22 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Acute Ischemic Stroke
- B2065Phase 21 trial
Tasly Pharmaceutical Group Co., Ltd · Acute Ischemic Stroke
- BB-031DTRI-031Phase 21 trial
Basking Biosciences, Inc. · Acute Ischemic Stroke
- HRS-4029Phase 21 trial
Beijing Suncadia Pharmaceuticals Co., Ltd · Acute Ischemic Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.